Company Encyclopedia
View More
name
Seer
SEER.US
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
746.92 B
SEER.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking41/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-25.74%E
    • Profit Margin-484.51%E
    • Gross Margin51.20%B
  • Growth ScoreC
    • Revenue YoY12.11%B
    • Net Profit YoY4.00%C
    • Total Assets YoY-19.51%E
    • Net Assets YoY-21.15%E
  • Cash ScoreC
    • Cash Flow Margin-20.64%D
    • OCF YoY12.11%B
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreA
    • Gearing Ratio11.92%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Seer, Inc. Earnings Call: Achievements Amid Challenges

    Seer, Inc. held its Q3 earnings call, highlighting achievements and challenges. The company reported strong demand for its Proteograph platform, a record number of publications, and increased instrument shipments. However, revenue growth was minimal at 2% year-over-year, impacted by government shutdowns and market uncertainties. Seer engaged in a share repurchase program, reducing shares outstanding by 14%. Despite challenges, the company remains optimistic, expecting full-year revenue between $17 million and $18 million, supported by a strong cash position of $251 million.

    Tip Ranks·
    US
    SEER
    +1.01%
    Tip Ranks·
    US
    SEER
    +1.01%

    Seer Inc. Showcases Deep Proteomics Advances at HUPO World Congress

    Seer Inc. will participate in the HUPO 2025 World Congress from November 10-12, 2025, showcasing its Proteograph platform. The company will present over a dozen scientific presentations, including two invited talks and sixteen poster presentations, focusing on the platform's contributions to cardiovascular, aging, and cancer research. This information is generated by Public Technologies and should not be considered financial or legal advice.

    Reuters·
    US
    SEER
    +1.01%
    Reuters·
    US
    SEER
    +1.01%

    Seer, Inc. Reports Modest Revenue Growth in Q3 2025

    Seer, Inc. reported Q3 2025 revenue of $4.1 million, a modest increase from the previous year. The company achieved a gross profit of $2.1 million with a 51% gross margin, while operating expenses decreased to $21.5 million. Despite a net loss of $18.2 million, improved from $21.3 million last year, Seer ended the quarter with $251.2 million in cash. The company maintains its 2025 revenue guidance of $17 million to $18 million, anticipating a 24% growth over 2024, driven by demand for its Proteograph Product Suite.

    Tip Ranks·
    US
    SEER
    +1.01%
    Tip Ranks·
    US
    SEER
    +1.01%

    Seer Inc reports results for the quarter ended September 30 - Earnings Summary

    Seer Inc reported a quarterly adjusted loss of 32 cents per share for the quarter ended September 30, slightly worse than the expected loss of 30 cents. Revenue increased by 2.2% to $4.12 million, surpassing analyst expectations of $4.00 million. The company incurred a total loss of $18.23 million. Analysts maintain a "buy" rating on the stock, with no negative revisions in earnings estimates over the past month. Year-to-date, Seer Inc shares have declined by 6.1%.

    Reuters·
    US
    SEER
    +1.01%
    Reuters·
    US
    SEER
    +1.01%

    Seer | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 4.121 M

    LB filings·
    US
    SEER
    +1.01%
    LB filings·
    US
    SEER
    +1.01%